Maze Therapeutics Inc. (MAZE)
NASDAQ: MAZEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MAZE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.72B
- EPS (TTM)
- -$2.62
- Dividend yield
- None
- 52-week range
- 21.95 – 53.65
- Day range
- 30.88 – 32.80
- Volume / Avg
- 818.93K / 737.14K
- Beta
- —
- Shares outstanding
- 54.68M
52-week range
MAZE stock today
On Nov 20, MAZE ended the session at $31.37, shedding $1.06 (3.27%), versus the S&P 500's 3.70% decline. Shares are 41.5% below their 52-week high of $53.65, set on Mar 16, 2026 and 42.9% above the 52-week low of $21.95, in the middle of the past year's range. MAZE is down 24.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 13.5%.
Maze Therapeutics has posted a net loss over the last twelve months (EPS of -$2.62), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Maze Therapeutics
Company profileMaze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 141
- IPO year
- 2025
- Website
- mazetx.com
Financial highlights
Full financialsMaze Therapeutics reported a net loss of $131.1 million, compared with net income of $52.2 million a year earlier. Diluted earnings per share came in at -$3.05, down from $1.25.
| Fiscal year | FY 2025 | FY 2024 |
|---|---|---|
| Revenue | — | $167.50M |
| Growth | — | — |
| Net income | $-131.12M | $52.23M |
| EPS (diluted) | $-3.05 | $1.25 |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$62.46+99.11%
- Strong buy 1
- Buy 13
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.79 vs $-0.78
- Surprise
- -1.28%
MAZE news
All MAZE newsMaze Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LYCALycia Therapeutics Inc. | 33.07 | +4.09% | $1.72B | vs MAZE |
| REPLReplimune Group Inc. | 19.07 | -0.83% | $1.81B | vs MAZE |
| COAGHemab Therapeutics Holdings Inc. | 39.29 | -1.43% | $1.84B | vs MAZE |
| BCRXBioCryst Pharmaceuticals Inc. | 7.22 | -1.37% | $1.86B | vs MAZE |
| VIRVir Biotechnology Inc. | 8.39 | -5.41% | $1.56B | vs MAZE |
| RXRXRecursion Pharmaceuticals Inc. Class A | 2.45 | -9.93% | $1.53B | vs MAZE |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs MAZE |
| WWBWindward Bio Group AG | 24.29 | +1.15% | $1.45B | vs MAZE |
Indexes, lists and sector
Maze Therapeutics stock FAQ
What is Maze Therapeutics's stock price today?
MAZE last traded at $31.37 as of Nov 20, 4:00 PM EST, down 3.27% on the day. Prices are delayed at least 15 minutes.
Who is Maze Therapeutics's CEO?
Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. is the chief executive officer of Maze Therapeutics Inc., which has about 141 employees.
What is the MAZE 52-week high?
The 52-week high for MAZE is $53.65 and the 52-week low is $21.95. The stock is currently 41.5% below its high.